Advert - Lundbeck – Case AUTH/3550/7/21

Concerns about the promotion of Vyepti at a virtual symposium

For promoting a pipeline product at a symposium session, and for that session to be available on demand on a third party website (without the pharmaceutical company’s permission), Lundbeck was ruled in breach of the following clauses of the 2019 Code:


Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.1 - Promoting a medicine prior to its marketing authorisation

Clause 9.1 - Failing to maintain high standards

Clause 9.10 - Failing to be sufficiently clear as to the company’s role and involvement